TRV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TRV is NOT a good buy right now at ~284.5 for an impatient buyer. The stock is extended near resistance (R1 ~284.8 / R2 ~289.2) with overbought short-term momentum (RSI6 ~72) and probabilistic pattern data pointing to weaker returns over the next week/month. If you already own it, holding is reasonable given strong Q4 results and supportive analyst targets, but for a fresh entry today, the risk/reward looks unfavorable versus waiting for a pullback toward ~277 (pivot) or ~270 (S1)—and since you’re unwilling to wait, the better move is to skip buying now.
Trend is bullish but stretched. Moving averages are strongly positive (SMA_5 > SMA_20 > SMA_200) and MACD histogram is positive and expanding (1.241), confirming an uptrend. However, RSI_6 at ~72 suggests the stock is short-term overbought/extended, and price is sitting just under immediate resistance (R1 284.795) with the next resistance at 289.218—limited upside room before hitting supply. Key levels: pivot support 277.637, then S1 270.478. Pattern-based forward odds provided are negative-biased (60% chance: -2.28% next week, -5.18% next month), which aligns with a potential mean-reversion pullback after the run.
Intellectia Proprietary Trading Signals
Strong 2025/Q4 earnings backdrop: higher net investment income, stable underwriting margins, and increased capital returns cited by analysts.
Multiple firms raised price targets post-Q4 (Citi to 315, KBW to 320, Evercore to 317, Argus to 295), supporting the idea that fundamentals remain solid.
Low implied volatility may make upside hedges/speculation cheaper if sentiment improves.
Event-driven risk: Winter Storm Fern could raise catastrophe losses for P&C insurers, a direct headline overhang for TRV.
Positioning/flows: hedge funds are reportedly selling aggressively (selling amount up ~1401% last quarter), which can cap upside.
Insider-related headline: an officer planned sale (~16,712 shares, ~$4.68M) can weigh on near-term sentiment.
Sector/cycle concerns from Wall Street: softening pricing, potential margin compression into 2026–2027, and meaningful competition (highlighted by Goldman downgrade and other neutral/underweight stances).
Latest quarter: 2025/Q4. Growth was strong: revenue $12.432B (+3.51% YoY), net income $2.477B (+19.89% YoY), EPS $11.06 (+23.44% YoY). This is a quality quarter with earnings leverage (profits and EPS growing much faster than revenue), consistent with improved loss experience and better investment income as noted by analysts.
Recent trend: price targets mostly moved up after Q4, but ratings are mixed and the Street is split between fundamental strength now vs. cyclical pressures ahead. Bullish/positive: KBW Outperform (PT 320), Evercore Outperform (PT 317), Argus Buy (PT 295). Neutral/cautious: Citi Neutral (PT 315), Mizuho Neutral (PT 304), Barclays Equal Weight (PT 312), Goldman downgraded to Neutral (PT 304). Bearish: JPMorgan Underweight (PT 305). Wall Street pros: stable underwriting, rising net investment income, and capital returns. Cons: expected slower organic premium growth, increasing competition in personal auto/commercial property, and potential margin compression as the P&C market softens.
